In general, although both in vivo and in vitro experimental and clinical evidence suggest that inhibiting NFE2L3 expression may impede the progression of thyroid cancer, the precise mechanism by which NFE2L3 exerts its pro-tumor effects remains unclear. The gene discussed is NFE2L3; the disease is thyroid gland carcinoma.